Mitigation Strategies for a Missed Meal Bolus in People with Type 1 Diabetes Using the Minimed ™ 780G System
Diabetes Technology & Therapeutics · 2026
DOI: 10.1177/15209156251395010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes Technology & Therapeutics, 2026. Verfasst von Bruno A Grassi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Nutrición, Diabetes y Metabolismo, Escuela de Medicina, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chi…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Insulin, Hypoglycemic Agents, Insulin Infusion Systems. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Medtronic External Research Program.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Postprandial glucose control remains a challenge in people with type 1 diabetes (T1D), even when using advanced hybrid closed-loop systems (AHCL) such as the MiniMed™ 780G (MM780G) system. Missed mealtime boluses are common and can significantly impair glycemic outcomes. This study aimed to evaluate a corrective postprandial bolus strategy for missed meal boluses using the MM780G system.
Methods
In a prospective, open-label, real-world study, 32 adults with T1D using the MM780G system completed three meal scenarios with standardized meals (∼60 g carbohydrates). The strategies were: (E1) premeal bolus (control), (E2) no bolus (relying on system automation), and (E3) delayed bolus (bolus covering 50% of carbohydrate content, 60 min postmeal). Each participant completed all strategies under remote supervision. Primary outcome was 4-h postprandial time in range (TIR, 70–180 mg/dL); secondary outcomes included time in tight range (TITR, 70–140 mg/dL), time above/below range, and adverse events.
Results
Premeal bolus (E1) achieved the highest TIR (85.5% ± 18.8%), significantly outperforming both E2 (52.3% ± 25.3%) and E3 (63.5% ± 24.0%, P < 0.001). E3 also showed significant improvement over E2 ( P < 0.001). TITR followed a similar pattern. Time between 54 and 70 mg/dL was slightly higher for E1 but remained within consensus goals. No significant differences in hypoglycemia (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departamento de Nutrición, Diabetes y Metabolismo, Escuela de Medicina, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
- Escuela de Salud Pública, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
- Medtronic, Diabetes Latin America, Santiago, Chile.
- Medtronic Diabetes, Northridge, California, USA.
- Medtronic International Trading Sarl, Tolochenaz, Switzerland.
Förderung
- Medtronic External Research Program
Zitieren
APA
Grassi, B. A., Onetto, M. T., Mora, G., Tapia, N., Passi, Á., Jofré, P., Castro, M., Kurtz, N., Vigersky, R., & Cohen, O. (2026). Mitigation Strategies for a Missed Meal Bolus in People with Type 1 Diabetes Using the Minimed ™ 780G System. Diabetes Technology & Therapeutics. https://doi.org/10.1177/15209156251395010
Vancouver
Grassi BA, Onetto MT, Mora G, Tapia N, Passi Á, Jofré P, et al. Mitigation Strategies for a Missed Meal Bolus in People with Type 1 Diabetes Using the Minimed ™ 780G System. Diabetes Technology & Therapeutics. 2026. doi:10.1177/15209156251395010
BibTeX
@article{Grassi2026,
author = {Grassi, Bruno A and Onetto, María Teresa and Mora, Germán and Tapia, Nicole and Passi, Álvaro and Jofré, Paulina and Castro, Matías and Kurtz, Natalie and Vigersky, Robert and Cohen, Ohad},
title = {Mitigation Strategies for a Missed Meal Bolus in People with Type 1 Diabetes Using the Minimed ™ 780G System},
journal = {Diabetes Technology & Therapeutics},
year = {2026},
doi = {10.1177/15209156251395010}
}
EUVIMED